
Biopharmaceutical stocks are in focus on Monday after Bristol-Myers Squibb (BMY) announced an $11 billion partnership with BioNTech (BNTX) at the world’s largest cancer conference, the American Society for Clinical Oncology (ASCO), in Chicago.
However, there are two other cancer-focused biopharma stocks, Actuate Therapeutics (ACTU) and PDS Biotechnology (PDSB), that analysts seem most bullish on for the next 12 months.